vs
PHIBRO ANIMAL HEALTH CORP（PAHC）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是PHIBRO ANIMAL HEALTH CORP的1.7倍（$622.0M vs $373.9M），Royalty Pharma plc净利率更高（34.4% vs 7.3%，领先27.1%），PHIBRO ANIMAL HEALTH CORP同比增速更快（20.9% vs 4.8%），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs 4.6%）
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
PAHC vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.7倍
$373.9M
营收增速更快
PAHC
高出16.1%
4.8%
净利率更高
RPRX
高出27.1%
7.3%
两年增速更快
PAHC
近两年复合增速
4.6%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $373.9M | $622.0M |
| 净利润 | $27.5M | $214.2M |
| 毛利率 | 35.5% | — |
| 营业利润率 | 13.5% | 62.4% |
| 净利率 | 7.3% | 34.4% |
| 营收同比 | 20.9% | 4.8% |
| 净利润同比 | 762.1% | 2.9% |
| 每股收益（稀释后） | $0.67 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PAHCRPRX
| Q4 25 | $373.9M | $622.0M | ||
| Q3 25 | $363.9M | $609.3M | ||
| Q2 25 | $378.7M | $578.7M | ||
| Q1 25 | $347.8M | $568.2M | ||
| Q4 24 | $309.3M | $593.6M | ||
| Q3 24 | $260.4M | $564.7M | ||
| Q2 24 | $273.2M | $537.3M | ||
| Q1 24 | $263.2M | $568.0M |
净利润PAHCRPRX
| Q4 25 | $27.5M | $214.2M | ||
| Q3 25 | $26.5M | $288.2M | ||
| Q2 25 | $17.2M | $30.2M | ||
| Q1 25 | $20.9M | $238.3M | ||
| Q4 24 | $3.2M | $208.2M | ||
| Q3 24 | $7.0M | $544.0M | ||
| Q2 24 | $752.0K | $102.0M | ||
| Q1 24 | $8.4M | $4.8M |
毛利率PAHCRPRX
| Q4 25 | 35.5% | — | ||
| Q3 25 | 32.9% | — | ||
| Q2 25 | 29.0% | — | ||
| Q1 25 | 30.1% | — | ||
| Q4 24 | 32.9% | — | ||
| Q3 24 | 32.1% | — | ||
| Q2 24 | 31.9% | — | ||
| Q1 24 | 30.2% | — |
营业利润率PAHCRPRX
| Q4 25 | 13.5% | 62.4% | ||
| Q3 25 | 14.1% | 70.1% | ||
| Q2 25 | 8.9% | 36.3% | ||
| Q1 25 | 9.6% | 94.0% | ||
| Q4 24 | 8.3% | 60.9% | ||
| Q3 24 | 6.8% | — | ||
| Q2 24 | 6.7% | 50.2% | ||
| Q1 24 | 7.6% | -13.0% |
净利率PAHCRPRX
| Q4 25 | 7.3% | 34.4% | ||
| Q3 25 | 7.3% | 47.3% | ||
| Q2 25 | 4.5% | 5.2% | ||
| Q1 25 | 6.0% | 41.9% | ||
| Q4 24 | 1.0% | 35.1% | ||
| Q3 24 | 2.7% | 96.3% | ||
| Q2 24 | 0.3% | 19.0% | ||
| Q1 24 | 3.2% | 0.8% |
每股收益（稀释后）PAHCRPRX
| Q4 25 | $0.67 | $0.49 | ||
| Q3 25 | $0.65 | $0.67 | ||
| Q2 25 | $0.43 | $0.07 | ||
| Q1 25 | $0.51 | $0.55 | ||
| Q4 24 | $0.08 | $0.46 | ||
| Q3 24 | $0.17 | $1.21 | ||
| Q2 24 | $0.02 | $0.23 | ||
| Q1 24 | $0.21 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.5M | $618.7M |
| 总债务越低越好 | $624.2M | $9.0B |
| 股东权益账面价值 | $332.4M | $9.7B |
| 总资产 | $1.4B | $19.6B |
| 负债/权益比越低杠杆越低 | 1.88× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资PAHCRPRX
| Q4 25 | $74.5M | $618.7M | ||
| Q3 25 | $85.3M | $938.9M | ||
| Q2 25 | $77.0M | $631.9M | ||
| Q1 25 | $70.4M | $1.1B | ||
| Q4 24 | $67.1M | $929.0M | ||
| Q3 24 | $89.8M | $950.1M | ||
| Q2 24 | $114.6M | $1.8B | ||
| Q1 24 | $98.7M | $843.0M |
总债务PAHCRPRX
| Q4 25 | $624.2M | $9.0B | ||
| Q3 25 | $628.0M | $8.9B | ||
| Q2 25 | $631.7M | $8.0B | ||
| Q1 25 | $635.4M | $7.6B | ||
| Q4 24 | $639.1M | $7.6B | ||
| Q3 24 | $295.2M | $7.6B | ||
| Q2 24 | $312.1M | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益PAHCRPRX
| Q4 25 | $332.4M | $9.7B | ||
| Q3 25 | $311.7M | $9.6B | ||
| Q2 25 | $285.7M | $9.5B | ||
| Q1 25 | $266.0M | $9.8B | ||
| Q4 24 | $246.8M | $10.3B | ||
| Q3 24 | $258.5M | $10.3B | ||
| Q2 24 | $256.6M | $9.8B | ||
| Q1 24 | $270.1M | $9.9B |
总资产PAHCRPRX
| Q4 25 | $1.4B | $19.6B | ||
| Q3 25 | $1.4B | $19.3B | ||
| Q2 25 | $1.4B | $18.3B | ||
| Q1 25 | $1.3B | $17.6B | ||
| Q4 24 | $1.3B | $18.2B | ||
| Q3 24 | $966.3M | $18.0B | ||
| Q2 24 | $982.2M | $17.7B | ||
| Q1 24 | $979.0M | $16.1B |
负债/权益比PAHCRPRX
| Q4 25 | 1.88× | 0.92× | ||
| Q3 25 | 2.01× | 0.93× | ||
| Q2 25 | 2.21× | 0.84× | ||
| Q1 25 | 2.39× | 0.78× | ||
| Q4 24 | 2.59× | 0.74× | ||
| Q3 24 | 1.14× | 0.74× | ||
| Q2 24 | 1.22× | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.4M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $8.3M | — |
| 自由现金流率自由现金流/营收 | 2.2% | — |
| 资本支出强度资本支出/营收 | 3.0% | — |
| 现金转化率经营现金流/净利润 | 0.70× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $47.3M | — |
8季度趋势，按日历期对齐
经营现金流PAHCRPRX
| Q4 25 | $19.4M | $827.1M | ||
| Q3 25 | $9.3M | $702.6M | ||
| Q2 25 | $21.3M | $364.0M | ||
| Q1 25 | $43.2M | $596.1M | ||
| Q4 24 | $3.1M | $742.5M | ||
| Q3 24 | $12.6M | $703.6M | ||
| Q2 24 | $28.4M | $658.2M | ||
| Q1 24 | $11.4M | $664.6M |
自由现金流PAHCRPRX
| Q4 25 | $8.3M | — | ||
| Q3 25 | $-4.5M | — | ||
| Q2 25 | $8.1M | — | ||
| Q1 25 | $35.4M | — | ||
| Q4 24 | $-4.7M | — | ||
| Q3 24 | $3.0M | — | ||
| Q2 24 | $15.4M | — | ||
| Q1 24 | $1.7M | — |
自由现金流率PAHCRPRX
| Q4 25 | 2.2% | — | ||
| Q3 25 | -1.2% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 10.2% | — | ||
| Q4 24 | -1.5% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 5.6% | — | ||
| Q1 24 | 0.6% | — |
资本支出强度PAHCRPRX
| Q4 25 | 3.0% | — | ||
| Q3 25 | 3.8% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 4.8% | — | ||
| Q1 24 | 3.7% | — |
现金转化率PAHCRPRX
| Q4 25 | 0.70× | 3.86× | ||
| Q3 25 | 0.35× | 2.44× | ||
| Q2 25 | 1.24× | 12.06× | ||
| Q1 25 | 2.07× | 2.50× | ||
| Q4 24 | 0.97× | 3.57× | ||
| Q3 24 | 1.81× | 1.29× | ||
| Q2 24 | 37.80× | 6.45× | ||
| Q1 24 | 1.36× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
